Valuation : Theralase Technologies Inc.

Market Cap 5.74Cr 4.15Cr 3.58Cr 3.36Cr 3.07Cr 392.27Cr 5.76Cr 40Cr 15Cr 201.24Cr 16Cr 15Cr 648.51Cr P/E 2026 *
-18.5x
P/E 2027 * 9.25x
Enterprise Value 5.74Cr 4.15Cr 3.58Cr 3.36Cr 3.07Cr 392.27Cr 5.76Cr 40Cr 15Cr 201.24Cr 16Cr 15Cr 648.51Cr EV / Sales 2026 *
73.1x
EV / Sales 2027 * 1.69x
Free-Float
79.6%
Yield 2026 *
-
Yield 2027 * -
1 day+2.78%
Current month+2.78%
1 month-28.85%
3 months-19.57%
6 months-30.19%
Current year+12.12%
1 week 0.18
Extreme 0.18
0.2
1 month 0.18
Extreme 0.175
0.26
Current year 0.16
Extreme 0.16
0.41
1 year 0.14
Extreme 0.145
0.41
3 years 0.14
Extreme 0.14
0.41
5 years 0.14
Extreme 0.14
0.48
10 years 0.12
Extreme 0.12
0.6
Manager TitleAgeSince
Chief Executive Officer - 29/06/2023
Director of Finance/CFO - 27/06/2019
Chief Executive Officer - 15/11/2021
Director TitleAgeSince
Chairman - -
Director/Board Member - 27/06/2019
Director/Board Member - 01/01/2008
Date Insider Type Main position Quantity % Market Cap. Importance
31/08/26 Option

Director

3,360 0.0011%
27/08/26 Buy

Chief Executive Officer

42,000 0.0142%
24/08/26 Option

Chief Financial Officer

29,000 0.0098%
Change 5-day change 1-year change 3-year change Capi.($)
+2.78%0.00%-5.13%-21.28% 4.15Cr
+0.80%-1.81%+29.77%+39.17% 141.3Cr
-4.76%-21.57%-47.02%-65.07% 18Cr
0.00%+0.49%-21.11%-47.99% 5.11Cr
Average -0.29%-5.72%-10.87%-23.79% 42.24Cr
Weighted average by Cap. +0.22%-3.85%+19.01%+23.70%

Financials

2026 *2027 *
Net sales 8L 6L 5L 5L 4L 5.37Cr 8L 54.35L 21.05L 2.75Cr 21.34L 20.87L 8.87Cr 3.39Cr 2.45Cr 2.11Cr 1.98Cr 1.81Cr 231.43Cr 3.4Cr 23Cr 9.07Cr 118.73Cr 9.2Cr 9Cr 382.61Cr
Net income -41.24L -29.79L -25.67L -24.14L -22.06L -28Cr -41.38L -2.85Cr -1.1Cr -14Cr -1.12Cr -1.09Cr -47Cr 69.01L 49.85L 42.96L 40.4L 36.92L 47Cr 69.24L 4.77Cr 1.85Cr 24Cr 1.87Cr 1.83Cr 78Cr
Net Debt - -
Logo Theralase Technologies Inc.
Theralase Technologies Inc. is a Canada-based clinical stage pharmaceutical company. The Company is engaged in the research and development of light, radiation, sound and drug-activated small molecule compounds and their associated formulations, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses, with minimal impact on surrounding healthy tissue. It operates through two divisions: the Drug Division and the Device Division. The Drug Division is responsible for the research and development of small molecules primarily for the treatment of cancer with assistance from the Device Division to develop medical lasers to activate them. The Device Division is responsible for the Company’s medical laser business, which researches, develops, manufactures and distributes cool laser therapy systems to healthcare practitioners, predominantly for the healing of pain.
Employees
20
Date Price Change Volume
04/26/04 CA$0.1850 +2.78% 1,77,002
03/26/03 CA$0.1800 -5.26% 1,97,631
02/26/02 CA$0.1900 +2.70% 2,78,002
01/26/01 CA$0.1850 +2.78% 2,50,027
31/26/31 CA$0.1800 -2.70% 2,29,049
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.1850CAD
Average target price
0.7000CAD
Spread / Average Target
+278.38%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!